; and (7) that provides recommendations for increasing public awareness and education of opioid use disorder in pregnancy, including available treatment resources in urban and rural areas. (b) No additional funds No additional funds are authorized to be appropriated for purposes of carrying out subsection (a). 3006. Guidelines for prescribing naloxone (a) In general Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall issue guidelines for prescribing an opioid overdose reversal drug. (b) Contents In issuing guidelines under subsection (a), the Secretary shall address the following: (1) Co-prescribing an opioid overdose reversal drug in conjunction with any prescribed opioid. (2) Dosage safety. (3) Prescribing an opioid overdose reversal drug to an individual other than a patient. (4) Standing orders. (5) Other distribution, education, and safety measures as determined necessary. 3007. Requiring a survey of substance use disorder treatment providers receiving Federal funding (a) In general The Secretary of Health and Human Services (in this section referred to as the Secretary ) shall conduct a survey of all entities that receive Federal funding for the purpose of providing substance use disorder treatment services. The survey shall direct such entities to provide the following information: (1) The length of time the entity has provided substance use disorder treatment services. (2) A detailed description of the patient population served by the entity, including but not limited to the number of patients, type of addictions, geographic area served, as well as gender, racial, ethnic and socioeconomic demographics of such patients. (3) A detailed description of the types of addiction for which the entity has the experience, capability, and capacity to provide such services. (4) An explanation of how the entity handles patients requiring treatment for a substance use disorder that the organization is not able to treat. (5) A description of what is